# Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

> **NCT01079325** · PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 170 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Polyneuropathy

## Interventions

- **DRUG:** SB-509
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT01079325
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-05
- **Final completion:** 2016-04
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2022-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079325, "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01079325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*